GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Steris PLC (NYSE:STE) » Definitions » ROE %
中文

Steris (Steris) ROE %

: 8.94% (As of Dec. 2023)
View and export this data going back to 1992. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Steris's annualized net income for the quarter that ended in Dec. 2023 was $563 Mil. Steris's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $6,297 Mil. Therefore, Steris's annualized ROE % for the quarter that ended in Dec. 2023 was 8.94%.

The historical rank and industry rank for Steris's ROE % or its related term are showing as below:

STE' s ROE % Range Over the Past 10 Years
Min: 1.7   Med: 9.61   Max: 13.05
Current: 9.18

During the past 13 years, Steris's highest ROE % was 13.05%. The lowest was 1.70%. And the median was 9.61%.

STE's ROE % is ranked better than
72.87% of 811 companies
in the Medical Devices & Instruments industry
Industry Median: 0.25 vs STE: 9.18

Steris ROE % Historical Data

The historical data trend for Steris's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Steris Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.52 12.38 10.91 4.68 1.70

Steris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.37 12.36 8.07 7.47 8.94

Competitive Comparison

For the Medical Devices subindustry, Steris's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Steris ROE % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Steris's ROE % distribution charts can be found below:

* The bar in red indicates where Steris's ROE % falls into.



Steris ROE % Calculation

Steris's annualized ROE % for the fiscal year that ended in Mar. 2023 is calculated as

ROE %=Net Income (A: Mar. 2023 )/( (Total Stockholders Equity (A: Mar. 2022 )+Total Stockholders Equity (A: Mar. 2023 ))/ count )
=107.03/( (6532.356+6077.198)/ 2 )
=107.03/6304.777
=1.70 %

Steris's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=562.972/( (6178.073+6415.396)/ 2 )
=562.972/6296.7345
=8.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Steris  (NYSE:STE) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=562.972/6296.7345
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(562.972 / 5582.58)*(5582.58 / 11357.8965)*(11357.8965 / 6296.7345)
=Net Margin %*Asset Turnover*Equity Multiplier
=10.08 %*0.4915*1.8038
=ROA %*Equity Multiplier
=4.95 %*1.8038
=8.94 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=562.972/6296.7345
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (562.972 / 717.156) * (717.156 / 864.648) * (864.648 / 5582.58) * (5582.58 / 11357.8965) * (11357.8965 / 6296.7345)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.785 * 0.8294 * 15.49 % * 0.4915 * 1.8038
=8.94 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Steris ROE % Related Terms

Thank you for viewing the detailed overview of Steris's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Steris (Steris) Business Description

Traded in Other Exchanges
Address
5960 Heisley Road, Mentor, OH, USA, 44060
Steris is an Ireland-domiciled medical device company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its 2015 inversion to Ireland, the firm continues to derive roughly 70% of revenue from its U.S. operations, 10% from the United Kingdom, and the remaining 20% from other international regions.
Executives
Richard C Breeden director 100 SOUTH WACKER, SUITE 1800, CHICAGO IL 60606
Cynthia L Feldmann director 17 WINTHROP ROAD, WAYLAND MA 01778
Jacqueline B Kosecoff director 5960 HEISLEY ROAD, MENTOR OH 44060
Mohsen Sohi director C/O STERIS CORPORATION, 5960 HEISLEY ROAD, MENTOR OH 44060
Esther M. Alegria director 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Cary L Majors officer: VP, N America Com Operations 5960 HEISLEY ROAD, MENTOR OH 44060
John Adam Zangerle director, officer: Sr. VP, Gen Counsel, and Sec. 5960 HEISLEY ROAD, MENTOR OH 44060
Michael J Tokich director, officer: Sr. Vice Pres., CFO C/O STERIS CORP, 5960 HEISLEY RD, MENTOR OH 44060
Karen L Burton officer: VP, Controller & CAO 5960 HEISLEY ROAD, MENTOR OH 44060
Renato Tamaro officer: V.P. & Corporate Treasurer 5960 HEISLEY ROAD, MENTOR OH 44060
Andrew Xilas officer: SVP and GM, Dental 5960 HEISLEY ROAD, MENTOR OH 44060
Paul Edward Martin director C/O UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422
Julia Madsen officer: Senior VP, Life Sciences 5960 HEISLEY ROAD, MENTOR OH 44060
David B Lewis director
Rosebrough Walter M Jr officer: President & CEO 5960 HEISLEY ROAD, MENTOR OH 44060